Logotype for Ushio Inc

Ushio (6925) Q4 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Ushio Inc

Q4 2025 earnings summary

9 Sep, 2026

Executive summary

  • FY2024 net sales decreased 1.0% year-over-year to ¥177.6 billion, with operating profit down 32.0% to ¥8.8 billion and profit attributable to owners falling 37.0% to ¥6.7 billion, but results surpassed internal forecasts due to improved efficiency and strategic business selection.

  • Comprehensive income turned negative at ¥(2,764) million, compared to ¥28,246 million in the prior year.

  • Profitability was impacted by investment deferrals in the semiconductor market, valuation losses from a business portfolio revamp, and inventory write-downs.

  • Inventory reduction and enhanced balance sheet management led to improved free cash flow.

  • The global economy remained uncertain, with mixed demand trends and ongoing geopolitical risks.

Financial highlights

  • FY2024 net sales: ¥177.6 billion, down 1.0% year-over-year; operating profit: ¥8.8 billion, down 32.0%; profit attributable to owners: ¥6.7 billion, down 37.0%.

  • Operating margin fell to 5.0% from 7.2% year-over-year; EPS decreased to ¥70.27 from ¥97.22; ROE dropped to 3.1% from 4.5%.

  • Gross profit declined to ¥62,215 million from ¥64,916 million; ordinary profit dropped 22.6% to ¥12,451 million.

  • Extraordinary income included a ¥9.5 billion gain on sale of investment securities; extraordinary losses included ¥5.7 billion in restructuring expenses.

  • Net assets decreased to ¥200,509 million, with an equity ratio of 67.4%.

Outlook and guidance

  • FY2025 net sales forecast: ¥170.0 billion (down 4.3% YoY); operating profit: ¥10.0 billion (up 13.3% YoY); profit attributable to owners: ¥7.0 billion (up 3.0% YoY).

  • Operating margin expected to rise to 5.9%; EPS forecast at ¥79.45; ROE at 3.5%.

  • Dividend floor set at ¥70 per share through FY2026; planned share buybacks of ¥20–30 billion for FY2025–FY2026.

  • Industrial Processes and Visual Imaging revenues are expected to decline, while earnings in Visual Imaging and Life Sciences are projected to improve.

  • Exchange rate assumptions are ¥140/USD and ¥155/EUR.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more